Lake Street analyst Thomas Flaten raised the firm’s price target on BioLife Solutions (BLFS) to $30 from $28 and keeps a Buy rating on the shares after the company reported Q3 results ahead of expectations and adjusted 2024 expectations to reflect recent divestitures and the improving financial profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions price target raised to $31 from $28 at TD Cowen
- BioLife Solutions Reports Strong Q3 2024 Results
- BioLife Solutions lowers FY24 revenue view to $98.0M-$100.0M from $99.0M-$101.0M
- BioLife Solutions reports Q3 ContOps GAAP EPS (4c), consensus (9c)
- BLFS Earnings this Week: How Will it Perform?